Seagen goes to Pfiz­er for $43B; Sanofi buys di­a­betes part­ner Proven­tion; Cri­sis avert­ed in SVB demise; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.